GLP-1 Agonist / Insulin Combination Agents (SOLIQUA, XULTOPHY)

Self-Administration - subcutaneous injection

Diagnosis considered for coverage:

SOLIQUA (100 units/mL insulin glargine and 33 mcg/mL lixisenatide) (step therapy)
XULTOPHY (100 units/mL insulin degludec and 3.6 mcg/mL liraglutide) (prior authorization)

  • Type 2 diabetes mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
    • Limitations of Use: SOLIQUA 100/33 has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. SOLIQUA 100/33 is not recommended for use in combination with any other product containing a GLP-1 receptor agonist. SOLIQUA 100/33 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. SOLIQUA 100/33 has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. SOLIQUA 100/33 has not been studied in combination with prandial insulin. 
    • Limitations of Use: XULTOPHY 100/3.6 is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rodent C-cell tumor findings to humans. XULTOPHY 100/3.6 is not recommended for use in combination with any other product containing liraglutide or another GLP-1 receptor agonist. XULTOPHY 100/3.6 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. XULTOPHY 100/3.6 has not been studied in combination with prandial insulin.
Coverage Criteria:

For diagnosis of type 2 diabetes mellitus (DM2):

  • Requested drug is being used for a Food and Drug Administration (FDA)-approved indication; AND
  • Trial and failure (of a minimum 30-day supply), contraindication, or intolerance to one metformin-containing agent.
Dosing:

DM2:

  • Soliqua:
    • In patients naïve to basal insulin or to a GLP-1 receptor agonist, currently on a GLP-1 receptor agonist or currently on less than 30 units of basal insulin daily:
      • The recommended starting dosage of SOLIQUA 100/33 is 15 units (15 units insulin glargine and 5 mcg lixisenatide) given subcutaneously once daily.
    • In patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 receptor agonist:
      • The recommended starting dosage of SOLIQUA 100/33 is 30 units (30 units insulin glargine and 10 mcg lixisenatide) given subcutaneously once daily.
    • The maximum daily dosage is of SOLIQUA 100/33 is 60 units (60 units insulin glargine and 20 mcg lixisenatide) given subcutaneously once daily.
  • Xultophy:
    • In patients naïve to basal insulin or to a GLP-1 receptor agonist:
      • The recommended starting dosage of XULTOPHY 100/3.6 is 10 units (10 units insulin degludec and 0.36 mg liraglutide) given subcutaneously once daily.
    • In patients currently on basal insulin daily, or a GLP-1 receptor agonist:
      • The recommended starting dosage of XULTOPHY 100/3.6 is 16 units (16 units insulin degludec and 0.58 mg liraglutide) given subcutaneously once daily.
    • The maximum daily dosage is of XULTOPHY 100/3.6 is 50 units (50 units insulin degludec and 1.8 mg liraglutide) given subcutaneously once daily.
Coverage Duration: 
  • One (1) Year 
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Policy Updates:
  • 12/01/2023 – New policy approved by WHA P&T Committee. (P&T, 11/14/23) 
References:
  1. Soliqua Prescribing Information. Sanofi-aventis U.S. LLC. Bridgewater, NJ. June 2022. 
  2. Xultophy Prescribing Information. Novo Nordisk Inc. Bagsvaerd, Denmark. June 2022. 

Last review date: December 1, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone